{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:36:54Z","timestamp":1792467414929,"version":"4.5.0"},"reference-count":213,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoX"],"abstract":"<jats:p>Cisplatin, a platinum-based compound, is a cornerstone of modern chemotherapy and remains widely used against a variety of solid tumors, including testicular, ovarian, lung, bladder, and head and neck cancers. Its anticancer activity is primarily attributed to the formation of DNA crosslinks, which obstruct replication and repair, ultimately leading to apoptosis. However, the clinical value of cisplatin is constrained by two major challenges: its toxic profile and the development of resistance. Cisplatin toxicity arises from its interaction not only with tumor DNA but also with proteins and nucleic acids in healthy tissues, resulting in a range of adverse effects, including, but not limited to, nephrotoxicity, ototoxicity, neurotoxicity, and gastrointestinal injury. In pediatric patients, permanent hearing loss represents a particularly debilitating complication. On the other hand, tumor cells can evade cisplatin cytotoxicity through diverse mechanisms, including reduced intracellular drug accumulation, enhanced DNA repair, detoxification by thiol-containing molecules, and alterations in apoptotic signaling. These resistance pathways severely compromise treatment outcomes and often necessitate alternative or combination strategies. This review examines the chemical structure of cisplatin, the molecular mechanisms of cisplatin cytotoxicity and cisplatin-induced resistance, as well as the main applications in cancer management and the complications associated with its clinical use.<\/jats:p>","DOI":"10.3390\/jox16010009","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T12:56:55Z","timestamp":1767877015000},"page":"9","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Cisplatin as a Xenobiotic Agent: Molecular Mechanisms of Actions and Clinical Applications in Oncology"],"prefix":"10.3390","volume":"16","author":[{"given":"Monia","family":"Cecati","sequence":"first","affiliation":[{"name":"Department of Human Sciences and Promotion of the Quality of Life, San Raffaele Roma University, 00166 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3941-0341","authenticated-orcid":false,"given":"Valentina","family":"Pozzi","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Polytechnic University of Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Pompei","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Polytechnic University of Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9943-3908","authenticated-orcid":false,"given":"Valentina","family":"Schiavoni","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Polytechnic University of Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5524-741X","authenticated-orcid":false,"given":"Stefania","family":"Fumarola","sequence":"additional","affiliation":[{"name":"Advanced Technology Center for Aging Research, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) INRCA, 60121 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Romagnoli","sequence":"additional","affiliation":[{"name":"Department of Life and Environmental Sciences, Polytechnic University of Marche, 60131 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7003-1230","authenticated-orcid":false,"given":"Giovanni","family":"Tossetta","sequence":"additional","affiliation":[{"name":"Department of Human Sciences and Promotion of the Quality of Life, San Raffaele Roma University, 00166 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0508-6523","authenticated-orcid":false,"given":"Angelo","family":"Montana","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences and Public Health, Section of Legal Medicine, Polytechnic University of Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6717-8899","authenticated-orcid":false,"given":"Alessandro","family":"Polizzi","sequence":"additional","affiliation":[{"name":"Department of General Surgery and Surgical-Medical Specialties, School of Dentistry, University of Catania, 95124 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3879-8647","authenticated-orcid":false,"given":"Davide","family":"Sartini","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Polytechnic University of Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2607-2734","authenticated-orcid":false,"given":"Roberto","family":"Campagna","sequence":"additional","affiliation":[{"name":"Department of Human Sciences and Promotion of the Quality of Life, San Raffaele Roma University, 00166 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0079-6603(01)67026-0","article-title":"Cisplatin: From DNA damage to cancer chemotherapy","volume":"67","author":"Cohen","year":"2001","journal-title":"Prog. Nucleic Acid Res. Mol. Biol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/205698a0","article-title":"Inhibition of Cell Division in Escherichia Coli by Electrolysis Products from a Platinum Electrode","volume":"205","author":"Rosenberg","year":"1965","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0021-9258(18)96186-7","article-title":"The inhibition of growth or cell division in Escherichia coli by different ionic species of platinum(IV) complexes","volume":"242","author":"Rosenberg","year":"1967","journal-title":"J. Biol. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/222385a0","article-title":"Platinum compounds: A new class of potent antitumour agents","volume":"222","author":"Rosenberg","year":"1969","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"102925","DOI":"10.1016\/j.bioorg.2019.102925","article-title":"Cisplatin: The first metal based anticancer drug","volume":"88","author":"Ghosh","year":"2019","journal-title":"Bioorg. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2478\/raon-2019-0018","article-title":"Cisplatin and beyond: Molecular mechanisms of action and drug resistance development in cancer chemotherapy","volume":"53","author":"Makovec","year":"2019","journal-title":"Radiol. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"9436","DOI":"10.1039\/C5CC01751C","article-title":"Cisplatin binding to human serum albumin: A structural study","volume":"51","author":"Ferraro","year":"2015","journal-title":"Chem. Commun."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/bdd.2197","article-title":"Interaction of platinum agents, cisplatin, carboplatin and oxaliplatin against albumin in vivo rats and in vitro study using inductively coupled plasma-mass spectrometory","volume":"40","author":"Kato","year":"2019","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Yin, W.J., Huang, Y.J., Zhu, Q., Lin, X.Q., Piao, H.L., Yu, Q.Q., Lai, C.H., Zhou, G.L., Zhou, L.Y., and Liu, K. (2024). Hypoalbuminemia and cisplatin-induced acute kidney injury. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1510477"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0277-5379(86)90389-5","article-title":"Pharmacokinetics of intra-arterial and intravenous cisplatin in head and neck cancer patients","volume":"22","author":"Gouyette","year":"1986","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1146\/annurev.pharmtox.48.080907.180426","article-title":"The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy","volume":"48","author":"Hall","year":"2008","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1039\/C4MT00238E","article-title":"Mechanisms of cell uptake and toxicity of the anticancer drug cisplatin","volume":"6","author":"Eljack","year":"2014","journal-title":"Metallomics"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"9062","DOI":"10.1002\/anie.200703271","article-title":"Interaction between platinum complexes and a methionine motif found in copper transport proteins","volume":"46","author":"Arnesano","year":"2007","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1124\/jpet.106.110346","article-title":"Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family)","volume":"319","author":"Yonezawa","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1124\/dmd.117.079384","article-title":"Expression of Organic Anion Transporter 1 or 3 in Human Kidney Proximal Tubule Cells Reduces Cisplatin Sensitivity","volume":"46","author":"Nieskens","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"855S","DOI":"10.1093\/ajcn\/88.3.855S","article-title":"Role of copper in human neurological disorders","volume":"88","author":"Desai","year":"2008","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"E2151","DOI":"10.1002\/hed.24026","article-title":"Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review","volume":"38","author":"Strojan","year":"2016","journal-title":"Head Neck"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Szturz, P., Cristina, V., Herrera Gomez, R.G., Bourhis, J., Simon, C., and Vermorken, J.B. (2019). Cisplatin Eligibility Issues and Alternative Regimens in Locoregionally Advanced Head and Neck Cancer: Recommendations for Clinical Practice. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00464"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1007\/s00405-017-4687-4","article-title":"The impact of cumulative dose of cisplatin on outcome of patients with head and neck squamous cell carcinoma","volume":"274","author":"Navran","year":"2017","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Guo, S.S., Tang, L.Q., Zhang, L., Chen, Q.Y., Liu, L.T., Guo, L., Mo, H.Y., Luo, D.H., Huang, P.Y., and Xiang, Y.Q. (2015). The impact of the cumulative dose of cisplatin during concurrent chemoradiotherapy on the clinical outcomes of patients with advanced-stage nasopharyngeal carcinoma in an era of intensity-modulated radiotherapy. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1964-8"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"107596","DOI":"10.1016\/j.oraloncology.2025.107596","article-title":"Adverse event profiles and management of cisplatin-based chemoradiotherapy in locally advanced head and neck squamous cell carcinoma: A systematic review","volume":"169","author":"Bossi","year":"2025","journal-title":"Oral. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1093\/annonc\/mdx360","article-title":"Long-term toxicity of cisplatin in germ-cell tumor survivors","volume":"28","author":"Chovanec","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"24332","DOI":"10.1038\/srep24332","article-title":"The Cumulative Cisplatin Dose Affects the Long-Term Survival Outcomes of Patients with Nasopharyngeal Carcinoma Receiving Concurrent Chemoradiotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Ngamphaiboon, N., Dechaphunkul, A., Setakornnukul, J., Dechaphunkul, T., Jiratrachu, R., Suktitipat, B., Jiarpinitnun, C., Pattaranutaporn, P., and Danchaivijitr, P. (2020). Optimal cumulative dose of cisplatin for concurrent chemoradiotherapy among patients with non-metastatic nasopharyngeal carcinoma: A multicenter analysis in Thailand. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07024-8"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Paken, J., Govender, C.D., Pillay, M., Feyasa, M., and Sewram, V. (2023). Cisplatin-associated ototoxicity amongst cervical cancer patients: A prospective cohort study in south Africa. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0283639"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejca.2016.09.023","article-title":"Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study","volume":"69","author":"Clemens","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1124\/pr.111.005637","article-title":"Cisplatin resistance: A cellular self-defense mechanism resulting from multiple epigenetic and genetic changes","volume":"64","author":"Shen","year":"2012","journal-title":"Pharmacol. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"153516","DOI":"10.1016\/j.tox.2023.153516","article-title":"Cytotoxicity and mechanism of action of metal complexes: An overview","volume":"492","author":"Abdolmaleki","year":"2023","journal-title":"Toxicology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"14298","DOI":"10.1073\/pnas.162491399","article-title":"Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals","volume":"99","author":"Ishida","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1124\/mol.106.022624","article-title":"Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin","volume":"70","author":"Holzer","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1124\/mol.62.5.1154","article-title":"The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae","volume":"62","author":"Lin","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"101626","DOI":"10.1016\/j.tranon.2023.101626","article-title":"Copper transporter Ctr1 contributes to enhancement of the sensitivity of cisplatin in esophageal squamous cell carcinoma","volume":"29","author":"Wang","year":"2023","journal-title":"Transl. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e30572","DOI":"10.1002\/jcb.30572","article-title":"Paraoxonase-2 shRNA-mediated gene silencing suppresses proliferation and migration, while promotes chemosensitivity in clear cell renal cell carcinoma cell lines","volume":"125","author":"Schiavoni","year":"2024","journal-title":"J. Cell. Biochem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"D1670","DOI":"10.1093\/nar\/gkae973","article-title":"Generic Diagramming Platform (GDP): A comprehensive database of high-quality biomedical graphics","volume":"53","author":"Jiang","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: Molecular mechanisms of action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1080\/08958378.2020.1737762","article-title":"Physiological responses to cisplatin using a mouse hypersensitivity model","volume":"32","author":"Lehmann","year":"2020","journal-title":"Inhal. Toxicol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0027-5107(78)90014-3","article-title":"Increased sensitivity of UV-repair-deficient human cells to DNA bound platinum products which unlike thymine dimers are not recognized by an endonuclease extracted from Micrococcus luteus","volume":"51","author":"Fraval","year":"1978","journal-title":"Mutat. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"102917","DOI":"10.1016\/j.redox.2023.102917","article-title":"Glutathione and peroxisome redox homeostasis","volume":"67","author":"Ferreira","year":"2023","journal-title":"Redox Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1096\/fj.02-0752rev","article-title":"Oxidative DNA damage: Mechanisms, mutation, and disease","volume":"17","author":"Cooke","year":"2003","journal-title":"FASEB J."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Campagna, R., Serritelli, E.N., Salvolini, E., Schiavoni, V., Cecati, M., Sartini, D., Pozzi, V., and Emanuelli, M. (2024). Contribution of the Paraoxonase-2 Enzyme to Cancer Cell Metabolism and Phenotypes. Biomolecules, 14.","DOI":"10.3390\/biom14020208"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1440-1681.2004.04127.x","article-title":"Role of non-selective adenosine receptor blockade and phosphodiesterase inhibition in cisplatin-induced nephrogonadal toxicity in rats","volume":"31","author":"Saad","year":"2004","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3109\/10408441003601836","article-title":"The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin","volume":"40","author":"Brozovic","year":"2010","journal-title":"Crit. Rev. Toxicol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1040-8428(02)00017-3","article-title":"Cancer and metals and metal compounds: Part I--carcinogenesis","volume":"42","author":"Desoize","year":"2002","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1002\/jps.20874","article-title":"Oxidative stress and apoptosis: Impact on cancer therapy","volume":"96","author":"Ozben","year":"2007","journal-title":"J. Pharm. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"21546","DOI":"10.1074\/jbc.M110.203745","article-title":"TWEAK induces apoptosis through a death-signaling complex comprising receptor-interacting protein 1 (RIP1), Fas-associated death domain (FADD), and caspase-8","volume":"286","author":"Ikner","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.freeradbiomed.2011.02.031","article-title":"Caveolin-1 mediates Fas-BID signaling in hyperoxia-induced apoptosis","volume":"50","author":"Zhang","year":"2011","journal-title":"Free Radic. Biol. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"166553","DOI":"10.1016\/j.bbadis.2022.166553","article-title":"PUMA overexpression dissociates thioredoxin from ASK1 to activate the JNK\/BCL-2\/BCL-XL pathway augmenting apoptosis in ovarian cancer","volume":"1868","author":"Chen","year":"2022","journal-title":"Biochim. Biophys. Acta Mol. Basis. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1089\/ars.2010.3596","article-title":"Redox regulation of the intrinsic pathway in neuronal apoptosis","volume":"14","author":"Franklin","year":"2011","journal-title":"Antioxid. Redox Signal."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.drup.2004.01.004","article-title":"ROS stress in cancer cells and therapeutic implications","volume":"7","author":"Pelicano","year":"2004","journal-title":"Drug Resist. Updat."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0006-2952(03)00508-2","article-title":"Chromosomal DNA fragmentation in apoptosis and necrosis induced by oxidative stress","volume":"66","author":"Higuchi","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10571-015-0166-x","article-title":"ROS and Autophagy: Interactions and Molecular Regulatory Mechanisms","volume":"35","author":"Li","year":"2015","journal-title":"Cell. Mol. Neurobiol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Dai, D., Chen, C., Lu, C., Guo, Y., Li, Q., and Sun, C. (2024). Apoptosis, autophagy, ferroptosis, and pyroptosis in cisplatin-induced ototoxicity and protective agents. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1430469"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41418-018-0106-7","article-title":"Single-cell analysis of pyroptosis dynamics reveals conserved GSDMD-mediated subcellular events that precede plasma membrane rupture","volume":"26","author":"Parthoens","year":"2019","journal-title":"Cell Death Differ."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41419-019-1761-4","article-title":"Propofol directly induces caspase-1-dependent macrophage pyroptosis through the NLRP3-ASC inflammasome","volume":"10","author":"Sun","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Yu, W., Zong, S., Zhou, P., Wei, J., Wang, E., Ming, R., and Xiao, H. (2022). Cochlear Marginal Cell Pyroptosis Is Induced by Cisplatin via NLRP3 Inflammasome Activation. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.823439"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"153368","DOI":"10.1016\/j.tox.2022.153368","article-title":"Knockdown and mutation of Pou4f3 gene mutation promotes pyroptosis of cochleae in cisplatin-induced deafness mice by NLRP3\/caspase-3\/GSDME pathway","volume":"482","author":"Yu","year":"2022","journal-title":"Toxicology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"109967","DOI":"10.1016\/j.cbi.2022.109967","article-title":"Cisplatin-induced pyroptosis is mediated via the CAPN1\/CAPN2-BAK\/BAX-caspase-9-caspase-3-GSDME axis in esophageal cancer","volume":"361","author":"Li","year":"2022","journal-title":"Chem. Biol. Interact."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"111698","DOI":"10.1016\/j.cellsig.2025.111698","article-title":"FTO triggers NLRP3\/GSDMD-dependent pyroptosis to enhance cisplatin-sensitivity in ovarian cancer","volume":"131","author":"Zhang","year":"2025","journal-title":"Cell Signal."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"715","DOI":"10.7150\/jca.66432","article-title":"Ophiopogonin B alleviates cisplatin resistance of lung cancer cells by inducing Caspase-1\/GSDMD dependent pyroptosis","volume":"13","author":"Cheng","year":"2022","journal-title":"J. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.toxlet.2021.07.010","article-title":"Autophagy-dependent ferroptosis contributes to cisplatin-induced hearing loss","volume":"350","author":"Jian","year":"2021","journal-title":"Toxicol. Lett."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s11658-021-00271-y","article-title":"Induction of ferroptosis by ATF3 elevation alleviates cisplatin resistance in gastric cancer by restraining Nrf2\/Keap1\/xCT signaling","volume":"26","author":"Fu","year":"2021","journal-title":"Cell. Mol. Biol. Lett."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Barbosa, L.A., Fiuza, P.P., Borges, L.J., Rolim, F.A., Andrade, M.B., Luz, N.F., Quintela-Carvalho, G., Lima, J.B., Almeida, R.P., and Chan, F.K. (2018). RIPK1-RIPK3-MLKL-Associated Necroptosis Drives Leishmania infantum Killing in Neutrophils. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01818"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s10495-015-1190-5","article-title":"Synergistic effect of apoptosis and necroptosis inhibitors in cisplatin-induced nephrotoxicity","volume":"21","author":"Tristao","year":"2016","journal-title":"Apoptosis"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Alassaf, N., and Attia, H. (2023). Autophagy and necroptosis in cisplatin-induced acute kidney injury: Recent advances regarding their role and therapeutic potential. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1103062"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/labinvest.2017.115","article-title":"Wogonin protects against cisplatin-induced acute kidney injury by targeting RIPK1-mediated necroptosis","volume":"98","author":"Meng","year":"2018","journal-title":"Lab. Investig."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Ramkumar, V., Mukherjea, D., Dhukhwa, A., and Rybak, L.P. (2021). Oxidative Stress and Inflammation Caused by Cisplatin Ototoxicity. Antioxidants, 10.","DOI":"10.3390\/antiox10121919"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2152607","DOI":"10.1080\/13510002.2022.2152607","article-title":"Glutathione metabolism rewiring protects renal tubule cells against cisplatin-induced apoptosis and ferroptosis","volume":"28","author":"Dong","year":"2023","journal-title":"Redox Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/jps.2600830620","article-title":"Determination of the acid dissociation constant for cis-diammineaquachloroplatinum(II) ion. A hydrolysis product of cisplatin","volume":"83","author":"Andersson","year":"1994","journal-title":"J. Pharm. Sci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0090-9556(25)06515-8","article-title":"Effect of intracellular chloride on the cellular pharmacodynamics of cis-diamminedichloroplatinum(II)","volume":"23","author":"Jennerwein","year":"1995","journal-title":"Drug Metab. Dispos."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/BF00255269","article-title":"Platinum drugs: Combined anti-lymphoproliferative and nephrotoxicity assay in rats","volume":"4","author":"Aggarwal","year":"1980","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1177\/41.7.8515048","article-title":"A histochemical approach to the mechanism of action of cisplatin and its analogues","volume":"41","author":"Aggarwal","year":"1993","journal-title":"J. Histochem. Cytochem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0891-5849(00)00317-8","article-title":"Mitochondrial free radical generation, oxidative stress, and aging","volume":"29","author":"Cadenas","year":"2000","journal-title":"Free Radic. Biol. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1155\/MBD.1998.77","article-title":"Calcium modulation of toxicities due to Cisplatin","volume":"5","author":"Aggarwal","year":"1998","journal-title":"Met. Based Drugs"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.bbagen.2013.03.020","article-title":"Biomarkers of lipid peroxidation in clinical material","volume":"1840","author":"Niki","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Minzi, O.M.S., Lyimo, T.E., Furia, F.F., Marealle, A.I., Kilonzi, M., Bwire, G.M., and Malichewe, C. (2020). Electrolytes supplementation can decrease the risk of nephrotoxicity in patients with solid tumors undergoing chemotherapy with cisplatin. BMC Pharmacol. Toxicol., 21.","DOI":"10.1186\/s40360-020-00448-9"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev-pathmechdis-051222-115023","article-title":"Apoptosis in Cancer Biology and Therapy","volume":"20","author":"Moyer","year":"2025","journal-title":"Annu. Rev. Pathol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/01926230701320337","article-title":"Apoptosis: A review of programmed cell death","volume":"35","author":"Elmore","year":"2007","journal-title":"Toxicol. Pathol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41580-023-00689-6","article-title":"A guide to cell death pathways","volume":"25","author":"Yuan","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/s41418-017-0025-z","article-title":"New insights into apoptosome structure and function","volume":"25","author":"Dorstyn","year":"2018","journal-title":"Cell Death Differ."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1124\/mol.59.4.657","article-title":"Is cisplatin-induced cell death always produced by apoptosis?","volume":"59","author":"Gonzalez","year":"2001","journal-title":"Mol. Pharmacol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/bs.apcsb.2021.01.003","article-title":"Intrinsic and extrinsic pathways of apoptosis: Role in cancer development and prognosis","volume":"125","author":"Kashyap","year":"2021","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","article-title":"Targeting apoptosis in cancer therapy","volume":"17","author":"Carneiro","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.semcancer.2017.04.012","article-title":"Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression","volume":"48","author":"Isakov","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.phrs.2007.04.001","article-title":"Classical PKC isoforms in cancer","volume":"55","author":"Fabbro","year":"2007","journal-title":"Pharmacol. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"BSR20160445","DOI":"10.1042\/BSR20160445","article-title":"Protein kinase C beta inhibits autophagy and sensitizes cervical cancer Hela cells to cisplatin","volume":"37","author":"Li","year":"2017","journal-title":"Biosci. Rep."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.dmpk.2019.09.001","article-title":"Cisplatin, rather than oxaliplatin, increases paracellular permeability of LLC-PK1 cells via activating protein kinase C","volume":"35","author":"Zhang","year":"2020","journal-title":"Drug Metab. Pharmacokinet"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1681\/ASN.2016030337","article-title":"Protein Kinase Cdelta Suppresses Autophagy to Induce Kidney Cell Apoptosis in Cisplatin Nephrotoxicity","volume":"28","author":"Zhang","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1476-5381.2008.00049.x","article-title":"Anti-apoptotic effects of protein kinase C-delta and c-fos in cisplatin-treated thyroid cells","volume":"156","author":"Muscella","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.2741\/3385","article-title":"Protein kinase C isoforms: Multi-functional regulators of cell life and death","volume":"14","author":"Reyland","year":"2009","journal-title":"Front. Biosci."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1126\/science.1072682","article-title":"Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases","volume":"298","author":"Johnson","year":"2002","journal-title":"Science"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1146\/annurev-biochem-081720-114505","article-title":"MAPK-Activated Protein Kinases: Servant or Partner?","volume":"91","author":"Ronkina","year":"2022","journal-title":"Annu. Rev. Biochem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1089\/ars.2010.3733","article-title":"Mitogen-activated protein kinases in mammalian oxidative stress responses","volume":"15","author":"Runchel","year":"2011","journal-title":"Antioxid. Redox Signal."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1593\/neo.91438","article-title":"c-Met overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1\/2","volume":"12","author":"Tang","year":"2010","journal-title":"Neoplasia"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.bbrc.2005.06.199","article-title":"Activation of ERK during DNA damage-induced apoptosis involves protein kinase Cdelta","volume":"334","author":"Basu","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.gene.2014.09.019","article-title":"The regulation of ERK and p-ERK expression by cisplatin and sorafenib in gastric cancer cells","volume":"552","author":"Tao","year":"2014","journal-title":"Gene"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Sun, C.Y., Cao, D., Ren, Q.N., Zhang, S.S., Zhou, N.N., Mai, S.J., Feng, B., and Wang, H.Y. (2021). Combination Treatment With Inhibitors of ERK and Autophagy Enhances Antitumor Activity of Betulinic Acid in Non-small-Cell Lung Cancer In Vivo and In Vitro. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.684243"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"11933","DOI":"10.1158\/0008-5472.CAN-07-5185","article-title":"ERK-dependent MKP-1-mediated cisplatin resistance in human ovarian cancer cells","volume":"67","author":"Wang","year":"2007","journal-title":"Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s002800100318","article-title":"Regulation of p53 target gene expression by cisplatin-induced extracellular signal-regulated kinase","volume":"48","author":"DeHaan","year":"2001","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.1038\/sj.onc.1209737","article-title":"Cisplatin induces PKB\/Akt activation and p38(MAPK) phosphorylation of the EGF receptor","volume":"25","author":"Levitzki","year":"2006","journal-title":"Oncogene"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1038\/sj.emboj.7601657","article-title":"A new p38 MAP kinase-regulated transcriptional coactivator that stimulates p53-dependent apoptosis","volume":"26","author":"Cuadrado","year":"2007","journal-title":"EMBO J."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"530","DOI":"10.4103\/jcrt.jcrt_792_22","article-title":"Cisplatin-based combination therapy for cancer","volume":"19","author":"Minerva","year":"2023","journal-title":"J. Cancer Res. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1042\/BJ20061778","article-title":"Regulation of p73-mediated apoptosis by c-Jun N-terminal kinase","volume":"405","author":"Jones","year":"2007","journal-title":"Biochem. J."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"44713","DOI":"10.1074\/jbc.M407672200","article-title":"c-Jun regulates the stability and activity of the p53 homologue, p73","volume":"279","author":"Toh","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.semcancer.2019.06.002","article-title":"Akt in cancer: Mediator and more","volume":"59","author":"Revathidevi","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"ref_105","first-page":"5988","article-title":"Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin","volume":"60","author":"Hayakawa","year":"2000","journal-title":"Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"201367","DOI":"10.4061\/2010\/201367","article-title":"Cellular responses to Cisplatin-induced DNA damage","volume":"2010","author":"Basu","year":"2010","journal-title":"J. Nucleic Acids"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1124\/mol.66.4.789","article-title":"Identification of cytoskeletal [14C]carboplatin-binding proteins reveals reduced expression and disorganization of actin and filamin in cisplatin-resistant cell lines","volume":"66","author":"Shen","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1006\/excr.1996.0211","article-title":"Cross-resistance, cisplatin accumulation, and platinum-DNA adduct formation and removal in cisplatin-sensitive and -resistant human hepatoma cell lines","volume":"226","author":"Johnson","year":"1996","journal-title":"Exp. Cell Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"9100","DOI":"10.1074\/jbc.M210284200","article-title":"Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling","volume":"278","author":"Mandic","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_110","first-page":"924","article-title":"Dysfunctional apoptosome activation in ovarian cancer: Implications for chemoresistance","volume":"62","author":"Liu","year":"2002","journal-title":"Cancer Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/(SICI)1097-0215(19990621)84:3<234::AID-IJC6>3.0.CO;2-9","article-title":"Heat-shock-protein-27 (hsp27) expression in ovarian carcinoma: Relation in response to chemotherapy and prognosis","volume":"84","author":"Arts","year":"1999","journal-title":"Int. J. Cancer"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0959-8049(99)00247-6","article-title":"Changes in p21WAF1, pRb, Mdm-2, Bax and Bcl-2 expression in cervical cancer cell lines transfected with a p53 expressing adenovirus","volume":"36","author":"Huang","year":"2000","journal-title":"Eur. J. Cancer"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1006\/bbrc.1999.0472","article-title":"Increased sensitivity of human colon cancer cells to DNA cross-linking agents after GRP78 up-regulation","volume":"257","author":"Belfi","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/(SICI)1097-0215(19981023)79:5<468::AID-IJC4>3.0.CO;2-Z","article-title":"Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy","volume":"79","author":"Gago","year":"1998","journal-title":"Int. J. Cancer"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1124\/mol.105.017525","article-title":"Identification by functional cloning from a retroviral cDNA library of cDNAs for ribosomal protein L36 and the 10-kDa heat shock protein that confer cisplatin resistance","volume":"69","author":"Shen","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3727\/096504007783438358","article-title":"The proteomic analysis of cisplatin resistance in breast cancer cells","volume":"16","author":"Smith","year":"2007","journal-title":"Oncol. Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.4161\/cc.9.19.13299","article-title":"Depletion of ribosomal protein L37 occurs in response to DNA damage and activates p53 through the L11\/MDM2 pathway","volume":"9","author":"Llanos","year":"2010","journal-title":"Cell Cycle"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Tossetta, G., Fantone, S., Marzioni, D., and Mazzucchelli, R. (2023). Cellular Modulators of the NRF2\/KEAP1 Signaling Pathway in Prostate Cancer. Front. Biosci., 28.","DOI":"10.31083\/j.fbl2807143"},{"key":"ref_119","first-page":"871","article-title":"NRF2 modulation in TRAMP mice: An in vivo model of prostate cancer","volume":"50","author":"Marzioni","year":"2022","journal-title":"Mol. Biol. Rep."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"106365","DOI":"10.1016\/j.phrs.2022.106365","article-title":"Natural and synthetic compounds in Ovarian Cancer: A focus on NRF2\/KEAP1 pathway","volume":"183","author":"Tossetta","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.canlet.2007.10.022","article-title":"Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: Implication to cancer cell resistance","volume":"260","author":"Cho","year":"2008","journal-title":"Cancer Lett."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1080\/14737140.2024.2438951","article-title":"NRF2\/KEAP1 signaling inhibitors in gynecologic cancers","volume":"24","author":"Fantone","year":"2024","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Tossetta, G., Fantone, S., Goteri, G., Giannubilo, S.R., Ciavattini, A., and Marzioni, D. (2023). The Role of NQO1 in Ovarian Cancer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24097839"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"175503","DOI":"10.1016\/j.ejphar.2023.175503","article-title":"Targeting the NRF2\/KEAP1 pathway in cervical and endometrial cancers","volume":"941","author":"Tossetta","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"4960","DOI":"10.1038\/s41467-021-24845-8","article-title":"Cisplatin-mediated activation of glucocorticoid receptor induces platinum resistance via MAST1","volume":"12","author":"Pan","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ccell.2018.06.012","article-title":"MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation","volume":"34","author":"Jin","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/onc.2011.384","article-title":"Molecular mechanisms of cisplatin resistance","volume":"31","author":"Galluzzi","year":"2012","journal-title":"Oncogene"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/0008-5472.CAN-05-2982","article-title":"Loss of DNA polymerase zeta causes chromosomal instability in mammalian cells","volume":"66","author":"Wittschieben","year":"2006","journal-title":"Cancer Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1215\/15228517-2009-015","article-title":"REV3L confers chemoresistance to cisplatin in human gliomas: The potential of its RNAi for synergistic therapy","volume":"11","author":"Wang","year":"2009","journal-title":"Neuro. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1038\/sj.emboj.7601127","article-title":"Apoptosis regulation in tetraploid cancer cells","volume":"25","author":"Castedo","year":"2006","journal-title":"EMBO J."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/1097-0215(20010320)95:2<92::AID-IJC1016>3.0.CO;2-9","article-title":"Expression of survivin in esophageal cancer: Correlation with the prognosis and response to chemotherapy","volume":"95","author":"Kato","year":"2001","journal-title":"Int. J. Cancer"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Aptullahoglu, E., and Kaygusuz, E. (2025). Synergistic MDM2-STAT3 Inhibition Demonstrates Strong Anti-Leukemic Efficacy in Acute Lymphoblastic Leukemia. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26178648"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"168056","DOI":"10.1016\/j.bbadis.2025.168056","article-title":"M1 macrophages enhance breast cancer chemoresistance via JAK-STAT3 signaling","volume":"1872","author":"Feng","year":"2026","journal-title":"Biochim. Biophys. Acta Mol. Basis. Dis."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nrc3818","article-title":"Revisiting STAT3 signalling in cancer: New and unexpected biological functions","volume":"14","author":"Yu","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ctrv.2017.06.003","article-title":"Targeting STAT3 with silibinin to improve cancer therapeutics","volume":"58","author":"Queralt","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.molonc.2009.02.004","article-title":"Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and management","volume":"3","author":"Lynch","year":"2009","journal-title":"Mol. Oncol."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Tossetta, G., and Inversetti, A. (2023). Ovarian Cancer: Advances in Pathophysiology and Therapies. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24108930"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Tossetta, G., Fantone, S., Montanari, E., Marzioni, D., and Goteri, G. (2022). Role of NRF2 in Ovarian Cancer. Antioxidants, 11.","DOI":"10.3390\/antiox11040663"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Fantone, S., Piani, F., Olivieri, F., Rippo, M.R., Sirico, A., Di Simone, N., Marzioni, D., and Tossetta, G. (2024). Role of SLC7A11\/xCT in Ovarian Cancer. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25010587"},{"key":"ref_140","first-page":"22","article-title":"The synergistic cytotoxic effect of cisplatin and honey bee venom on human ovarian cancer cell line A2780cp","volume":"3","author":"Alizadehnohi","year":"2012","journal-title":"J. Venom Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/bjc.2013.10","article-title":"Anticancer efficacy of cisplatin and trichostatin A or 5-aza-2\u2032-deoxycytidine on ovarian cancer","volume":"108","author":"Meng","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.bbrc.2012.06.047","article-title":"Synergistic cytotoxic action of cisplatin and withaferin A on ovarian cancer cell lines","volume":"423","author":"Kakar","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"154701","DOI":"10.1016\/j.phymed.2023.154701","article-title":"Shikonin and cisplatin synergistically overcome cisplatin resistance of ovarian cancer by inducing ferroptosis via upregulation of HMOX1 to promote Fe(2+) accumulation","volume":"112","author":"Ni","year":"2023","journal-title":"Phytomedicine"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s13048-024-01509-x","article-title":"The synergistic mechanisms of propofol with cisplatin or doxorubicin in human ovarian cancer cells","volume":"17","author":"Sue","year":"2024","journal-title":"J. Ovarian Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2147\/OTT.S406009","article-title":"Esomeprazole Alleviates Cisplatin Resistance by Inhibiting the AKT\/mTOR Pathway in Ovarian Cancer Cells","volume":"16","author":"Duan","year":"2023","journal-title":"Onco. Targets Ther."},{"key":"ref_146","first-page":"2051","article-title":"Synergistic effect of Tripterygium glycosides and cisplatin on drug-resistant human epithelial ovarian cancer via ILK\/GSK3beta\/Slug signal pathway","volume":"14","author":"Yu","year":"2022","journal-title":"Am. J. Transl. Res."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/S0140-6736(05)66546-4","article-title":"Breast cancer","volume":"365","author":"Veronesi","year":"2005","journal-title":"Lancet"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1007\/s13577-023-00892-9","article-title":"Paraoxonase-2 is upregulated in triple negative breast cancer and contributes to tumor progression and chemoresistance","volume":"36","author":"Campagna","year":"2023","journal-title":"Hum. Cell"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"108513","DOI":"10.1016\/j.mrrev.2024.108513","article-title":"Mechanistic insights into cisplatin response in breast tumors: Molecular determinants and drug\/nanotechnology-based therapeutic opportunities","volume":"794","author":"Hashemi","year":"2024","journal-title":"Mutat. Res. Rev. Mutat. Res."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1038\/sj.onc.1206933","article-title":"Cisplatin: Mode of cytotoxic action and molecular basis of resistance","volume":"22","author":"Siddik","year":"2003","journal-title":"Oncogene"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1038\/d41586-020-03152-0","article-title":"Lung cancer","volume":"587","author":"Brody","year":"2020","journal-title":"Nature"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1200\/JCO.2011.40.4905","article-title":"Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: The COCIS meta-analysis of individual patient data","volume":"30","author":"Rossi","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/jcpt.12781","article-title":"The effect of rapid infusion of cisplatin on nephrotoxicity in patients with lung carcinoma","volume":"44","author":"Mense","year":"2019","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1378\/chest.128.4.2268","article-title":"Double-cycle, high-dose ifosfamide, carboplatin, and etoposide followed by peripheral blood stem-cell transplantation for small cell lung cancer","volume":"128","author":"Iwasaki","year":"2005","journal-title":"Chest"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1200\/JCO.2001.19.1.119","article-title":"Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer","volume":"19","author":"Kosmas","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group","volume":"26","author":"Pignon","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"16281","DOI":"10.1073\/pnas.0905653106","article-title":"Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment","volume":"106","author":"Bertolini","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/odi.15156","article-title":"Impact of Topical Fluocinonide on Oral Lichen Planus Evolution: Randomized Controlled Clinical Trial","volume":"31","author":"Polizzi","year":"2025","journal-title":"Oral. Dis."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1111\/odi.14758","article-title":"Analysis of oral lichen planus severity on micro-RNA linked with malignant transformation risks","volume":"30","author":"Polizzi","year":"2024","journal-title":"Oral. Dis."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1002\/hed.26144","article-title":"Oligometastatic head and neck cancer: Comprehensive review","volume":"42","author":"Packianathan","year":"2020","journal-title":"Head Neck"},{"key":"ref_161","first-page":"1211","article-title":"Paraoxonase-2 expression in oral squamous cell carcinoma","volume":"36","author":"Campagna","year":"2023","journal-title":"Hum. Cell"},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Campagna, R., Belloni, A., Pozzi, V., Salvucci, A., Notarstefano, V., Togni, L., Mascitti, M., Sartini, D., Giorgini, E., and Salvolini, E. (2022). Role Played by Paraoxonase-2 Enzyme in Cell Viability, Proliferation and Sensitivity to Chemotherapy of Oral Squamous Cell Carcinoma Cell Lines. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24010338"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"125726","DOI":"10.1016\/j.saa.2025.125726","article-title":"Deepening Cisplatin sensitivity on Oral Squamous cell Carcinoma cell lines after PON2 knockdown: A FTIRM investigation","volume":"330","author":"Belloni","year":"2025","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11864-023-01051-w","article-title":"Treatment Considerations for Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin","volume":"24","author":"Kim","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"114778","DOI":"10.1016\/j.biopha.2023.114778","article-title":"New advances into cisplatin resistance in head and neck squamous carcinoma: Mechanisms and therapeutic aspects","volume":"163","author":"Hu","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1111\/cas.14639","article-title":"Cancer stem cells and their niche in the progression of squamous cell carcinoma","volume":"111","author":"Oshimori","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1017\/erm.2023.4","article-title":"Identity matters: Cancer stem cells and tumour plasticity in head and neck squamous cell carcinoma","volume":"25","author":"Salem","year":"2023","journal-title":"Expert Rev. Mol. Med."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1111\/odi.14209","article-title":"Epithelial-mesenchymal transition and cancer stem cells: A route to acquired cisplatin resistance through epigenetics in HNSCC","volume":"29","author":"Fernandes","year":"2023","journal-title":"Oral. Dis."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/B978-0-12-802997-8.00023-2","article-title":"Glioblastoma","volume":"134","author":"Wirsching","year":"2016","journal-title":"Handb. Clin. Neurol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"e6261","DOI":"10.1097\/MD.0000000000006261","article-title":"Continuous dose-intense temozolomide and cisplatin in recurrent glioblastoma patients","volume":"96","author":"Wang","year":"2017","journal-title":"Medicine"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"e1208876","DOI":"10.1080\/2162402X.2016.1208876","article-title":"Repurposing platinum-based chemotherapies for multi-modal treatment of glioblastoma","volume":"5","author":"Roberts","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Roda, D., Veiga, P., Melo, J.B., Carreira, I.M., and Ribeiro, I.P. (2024). Principles in the Management of Glioblastoma. Genes, 15.","DOI":"10.3390\/genes15040501"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ijrobp.2011.10.054","article-title":"Glioblastoma treatment: Bypassing the toxicity of platinum compounds by using liposomal formulation and increasing treatment efficiency with concomitant radiotherapy","volume":"84","author":"Charest","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Campagna, R., Bacchetti, T., Salvolini, E., Pozzi, V., Molinelli, E., Brisigotti, V., Sartini, D., Campanati, A., Ferretti, G., and Offidani, A. (2020). Paraoxonase-2 Silencing Enhances Sensitivity of A375 Melanoma Cells to Treatment with Cisplatin. Antioxidants, 9.","DOI":"10.3390\/antiox9121238"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/pcmr.12993","article-title":"Nicotinamide N-methyltransferase gene silencing enhances chemosensitivity of melanoma cell lines","volume":"34","author":"Campagna","year":"2021","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/DSS.0000000000000799","article-title":"Cisplatin and Cetuximab Treatment for Metastatic Cutaneous Squamous Cell Carcinoma: A Systematic Review","volume":"43","author":"Trodello","year":"2017","journal-title":"Dermatol. Surg."},{"key":"ref_178","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"115337","DOI":"10.1016\/j.biopha.2023.115337","article-title":"A state-of-art of underlying molecular mechanisms and pharmacological interventions\/nanotherapeutics for cisplatin resistance in gastric cancer","volume":"166","author":"Gupta","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"e00094","DOI":"10.1042\/BSR20130102","article-title":"PAK4 confers cisplatin resistance in gastric cancer cells via PI3K\/Akt- and MEK\/ERK-dependent pathways","volume":"34","author":"Fu","year":"2014","journal-title":"Biosci. Rep."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"174631","DOI":"10.1016\/j.ejphar.2021.174631","article-title":"Flotillin-1 promotes progression and dampens chemosensitivity to cisplatin in gastric cancer via ERK and AKT signaling pathways","volume":"916","author":"Wei","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s13277-014-2496-6","article-title":"RKIP promotes cisplatin-induced gastric cancer cell death through NF-kappaB\/Snail pathway","volume":"36","author":"Liu","year":"2015","journal-title":"Tumour Biol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"105610","DOI":"10.1016\/j.biocel.2019.105610","article-title":"Cisplatin induces chemoresistance through the PTGS2-mediated anti-apoptosis in gastric cancer","volume":"116","author":"Lin","year":"2019","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"107443","DOI":"10.1016\/j.intimp.2021.107443","article-title":"PD-1\/PD-L1 enhanced cisplatin resistance in gastric cancer through PI3K\/AKT mediated P-gp expression","volume":"94","author":"Wu","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Li, J., Zhang, Y., Ye, F., Qian, P., Qin, Z., Li, D., Ye, L., and Feng, L. (2023). DKK1 Promotes Epithelial-Mesenchymal Transition and Cisplatin Resistance in Gastric Cancer via Activation of the PI3K\/AKT Pathway. Cancers, 15.","DOI":"10.3390\/cancers15194756"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1177\/00031348221148359","article-title":"Management of Gastric Cancer","volume":"89","author":"Hall","year":"2023","journal-title":"Am. Surg."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00280-023-04572-1","article-title":"Mechanism of cisplatin resistance in gastric cancer and associated microRNAs","volume":"92","author":"Liu","year":"2023","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Pozzi, V., Campagna, R., Sartini, D., and Emanuelli, M. (2022). Nicotinamide N-Methyltransferase as Promising Tool for Management of Gastrointestinal Neoplasms. Biomolecules, 12.","DOI":"10.3390\/biom12091173"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"803","DOI":"10.7326\/0003-4819-86-6-803","article-title":"Cis-diamminedichloroplatinum (II). A new anticancer drug","volume":"86","author":"Rozencweig","year":"1977","journal-title":"Ann. Intern. Med."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.urology.2020.10.002","article-title":"Contemporary Trends in Presentation and Management of Spermatocytic Seminoma","volume":"146","author":"Patel","year":"2020","journal-title":"Urology"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"102054","DOI":"10.1016\/j.ctrv.2020.102054","article-title":"Testicular cancer: Determinants of cisplatin sensitivity and novel therapeutic opportunities","volume":"88","author":"Gietema","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0140-6736(25)00455-6","article-title":"Testicular cancer","volume":"406","author":"Chavarriaga","year":"2025","journal-title":"Lancet"},{"key":"ref_193","doi-asserted-by":"crossref","unstructured":"Tossetta, G., and Mazzucchelli, R. (2022). Pathology of Urologic Cancers. Cancers, 14.","DOI":"10.3390\/cancers14153751"},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"Fumarola, S., Cecati, M., Sartini, D., Ferretti, G., Milanese, G., Galosi, A.B., Pozzi, V., Campagna, R., Morresi, C., and Emanuelli, M. (2020). Bladder Cancer Chemosensitivity is Affected by Paraoxonase-2 Expression. Antioxidants, 9.","DOI":"10.3390\/antiox9020175"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12943-022-01517-9","article-title":"Targeting HNRNPU to overcome cisplatin resistance in bladder cancer","volume":"21","author":"Shi","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1442-2050.2009.01003.x","article-title":"Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma","volume":"23","author":"Li","year":"2010","journal-title":"Dis. Esophagus"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.cbi.2007.07.014","article-title":"Dimethylthiourea protects against mitochondrial oxidative damage induced by cisplatin in liver of rats","volume":"170","author":"Martins","year":"2007","journal-title":"Chem. Biol. Interact."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1191\/0748233705th216oa","article-title":"The activities of liver adenosine deaminase, xanthine oxidase, catalase, superoxide dismutase enzymes and the levels of malondialdehyde and nitric oxide after cisplatin toxicity in rats: Protective effect of caffeic acid phenethyl ester","volume":"21","author":"Yilmaz","year":"2005","journal-title":"Toxicol. Ind. Health"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.tox.2006.11.073","article-title":"Simvastatin attenuates cisplatin-induced kidney and liver damage in rats","volume":"230","author":"Iseri","year":"2007","journal-title":"Toxicology"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.phrs.2005.12.005","article-title":"Propionyl-L-carnitine prevents the progression of cisplatin-induced cardiomyopathy in a carnitine-depleted rat model","volume":"53","author":"Aleisa","year":"2006","journal-title":"Pharmacol. Res."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1093\/ndt\/12.12.2478","article-title":"Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application","volume":"12","author":"Kuhlmann","year":"1997","journal-title":"Nephrol. Dial. Transplant"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1634\/theoncologist.2016-0319","article-title":"A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity","volume":"22","author":"Crona","year":"2017","journal-title":"Oncologist"},{"key":"ref_203","doi-asserted-by":"crossref","unstructured":"Money, M.E., Hamroun, A., Shu, Y., Matthews, C., Ahmed Eltayeb, S., Ciarimboli, G., and Metz, C.N. (2021). Case Report and Supporting Documentation: Acute Kidney Injury Manifested as Oliguria Is Reduced by Intravenous Magnesium Before Cisplatin. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.607574"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1177\/1060028014533303","article-title":"Rates of Renal Toxicity in Cancer Patients Receiving Cisplatin With and Without Mannitol","volume":"48","author":"Morgan","year":"2014","journal-title":"Ann. Pharmacother."},{"key":"ref_205","first-page":"73","article-title":"High-dose cisplatin therapy using mannitol versus furosemide diuresis: Comparative pharmacokinetics and toxicity","volume":"65","author":"Ostrow","year":"1981","journal-title":"Cancer Treat. Rep."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/BF00877717","article-title":"Loop diuretics versus others in the treatment of congestive heart failure after myocardial infarction","volume":"7","author":"Reyes","year":"1993","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1080\/02841860902806609","article-title":"Persistent neuropathy after treatment with cisplatin and oxaliplatin","volume":"48","author":"Brouwers","year":"2009","journal-title":"Acta Oncol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1634\/theoncologist.2014-0044","article-title":"Platinum-induced neurotoxicity and preventive strategies: Past, present, and future","volume":"20","author":"Avan","year":"2015","journal-title":"Oncologist"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.redox.2014.01.006","article-title":"Oxidative stress and nerve damage: Role in chemotherapy induced peripheral neuropathy","volume":"2","author":"Areti","year":"2014","journal-title":"Redox Biol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"111079","DOI":"10.1016\/j.fct.2019.111079","article-title":"Overview of cisplatin-induced neurotoxicity and ototoxicity, and the protective agents","volume":"136","author":"Santos","year":"2020","journal-title":"Food Chem. Toxicol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s00405-016-4117-z","article-title":"Platinum-induced ototoxicity: A review of prevailing ototoxicity criteria","volume":"274","author":"Waissbluth","year":"2017","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1016\/j.ejca.2003.08.009","article-title":"Predicting cisplatin ototoxicity in children: The influence of age and the cumulative dose","volume":"40","author":"Li","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1158\/1078-0432.CCR-14-1298","article-title":"Cisplatin-induced antitumor immunomodulation: A review of preclinical and clinical evidence","volume":"20","author":"Adusumilli","year":"2014","journal-title":"Clin. Cancer Res."}],"container-title":["Journal of Xenobiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2039-4713\/16\/1\/9\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T13:17:47Z","timestamp":1767878267000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2039-4713\/16\/1\/9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":213,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["jox16010009"],"URL":"https:\/\/doi.org\/10.3390\/jox16010009","relation":{},"ISSN":["2039-4713"],"issn-type":[{"value":"2039-4713","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]}}}